A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB MONOTHERAPY PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH PLACEBO PLUS BSC IN SUBJECTS WITH WELL-DIFFERENTIATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS (PNETS), WHO HAVE PROGRESSED ON OR FOLLOWING PRIOR TREATMENT WITH EVEROLIMUS AND/OR SUNITINIB

Registry ID

200984

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Last update

2015-02-11

Conditions

• PANCREATIC NEUROENDOCRINE TUMORS

Related clinical trials

• A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELZUTIFAN (MK-6482, FORMERLY PT2977) MONOTHERAPY IN PARTICIPANTS WITH ADVANCED PHEOCHROMOCYTOMA/PARAGANGLIOMA (PPGL), PANCREATIC NEUROENDOCRINE TUMOR (PNET), VON HIPPEL-LINDAU (VHL) DISEASE-ASSOCIATED TUMORS, ADVANCED GASTROINTESTINAL STROMAL TUMOR (WT GIST), OR ADVANCED SOLID TUMORS WITH HIF-2A RELATED GENETIC ALTERATIONS
• A PHASE III MULITCENTER, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUTATHERA IN PATIENTS WITH GRADE 2 AND GRADE 3 ADVANCED GEP-NET

View on source registry